CO2 Solutions Announces Additional Notice of Allowance for Danish Intellectual Property

TSX-V: CST                                                                                                                              

QUEBEC CITY, QC, March 8, 2016 /CNW/ - CO₂ Solutions Inc. (or the "Corporation") (TSX-V: CST), the leader in the field of enzyme-enabled carbon capture technology, today announced it has received a notice of allowance for an additional Danish Utility Model (intellectual property rights) N° BA201400177 - SYSTEM FOR CO2 CAPTURE USING PACKED REACTOR AND ABSORPTION MIXTURE WITH MICRO-PARTICLES INCLUDING BIOCATALYSTS - from the Danish Patent Office. 

This utility model, relating more specifically to the use of enzyme particles in absorption and desorption units of a CO₂ capture system will provide additional depth to CO₂ Solutions' extensive intellectual property portfolio, providing broad coverage for enzyme-accelerated processes for carbon capture.  CO₂ Solutions believes this utility model could have significant additional value relative to one or more CO₂ capture projects currently underway in Denmark that the Corporation believes may be infringing on the CO₂ Solutions proprietary technology, including operations covered by this utility model.

Obtaining a positive decision on this second Danish utility model is all the more notable given that, once again, a leading European biotech company filed numerous documents and arguments against the pending CO₂ Solutions application. Obtaining the allowance despite significant opposition further illustrates the strength and value of CO₂ Solutions' intellectual property surrounding its innovative technologies. In addition, CO₂ Solutions has numerous other patents/utility model pending in Denmark and Europe.

"This is a second confirmation and additional clear validation of the robustness of our patent portfolio, and the uniqueness of our technology" stated Evan Price, President and Chief Executive Officer of CO₂ Solutions. "This second granted utility model adds additional depth to an already strong portfolio that, we believe, effectively covers the viable routes to commercialization of carbonic anhydrase enzyme-based systems for the capture of CO₂. Our competitors should have no doubt that we will continue to defend our IP vigorously whenever and wherever necessary."

About CO₂ Solutions Inc.
CO₂ Solutions is an innovator in the field of enzyme-enabled carbon capture and has been actively working to develop and commercialize the technology for stationary sources of carbon pollution.  CO₂ Solutions' technology lowers the cost barrier to Carbon Capture, Sequestration and Utilization (CCSU), positioning it as a viable CO₂ mitigation tool, as well as enabling industry to derive profitable new products from these emissions.  CO₂ Solutions has built an extensive patent portfolio covering the use of carbonic anhydrase, or analogues thereof, for the efficient post-combustion capture of carbon dioxide with low‐energy aqueous solvents.  Further information can be found at www.co2solutions.com.

CO₂ Solutions Forward-looking Statements
Certain statements in this news release may be forward-looking. These statements relate to future events or CO₂ Solutions' future economic performance and reflect the current assumptions and expectations of management. Certain unknown factors may affect the events, economic performance and results of operation described herein. CO₂ Solutions undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE CO2 Solutions Inc.

Investor Relations and Media Contact: CO2 Solutions: Thom Skinner, 418-842-3456, ext. 223, [email protected], www.co2solutions.com; or NATIONAL Equicom, Marc Lakmaaker, 416-848-1397, [email protected]